Post by Bristol Myers Squibb on X
Bristol Myers Squibb@bmsnews
X#MEDIA: @US_FDA has approved the removal of REMS and streamlined patient monitoring requirements for our #CARTcelltherapies, a landmark update that will help foster increased patient access for this important treatment modality. t.co

25 likes1 repliesPosted Jun 27, 2025